Last updated on July 2019

Safety of Intranodal ECI-006 in Melanoma Patients

Brief description of study

The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens.

In Cohort 1, ECI-006 will be administered 5 times by intranodal injection in melanoma patients after resection of their tumor.

In Cohort 2, ECI-006 will be administered 9 times by intranodal injection on top of standard of care pembrolizumab in metastatic melanoma patients with stable disease after 6 to 12 months pembrolizumab treatment.

ECI-006 activates key immunologically active cells to direct the immune system against the cancer. Expected potential risks for ECI-006 are non-serious and related to the local administration of the product. Hence, the therapy suggested here has the promise to offer considerable benefit to patients without any major risk.

Clinical Study Identifier: NCT03394937

Find a site near you

Start Over


Barcelona, Spain
  Connect »